




Docket No.: 216143US0DIV

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313



ATTORNEYS AT LAW

RE: Application Serial No.: 09/987,601
Applicants: Philippe MOULLIER, et al.
Filing Date: November 15, 2001
For: BIOCOMPATIBLE IMPLANT FOR THE
EXPRESSION AND IN VIVO SECRETION OF A
THERAPEUTIC SUBSTANCE
Group Art Unit: 1636
Examiner: QUAN, C.X.

RECEIVED
AUG 28 2003
TECH CENTER 1636/2233

SIR:

Attached hereto for filing are the following papers:

RESPONSE TO REQUIREMENT FOR RESTRICTION

Our check in the amount of \$0.00 is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R. 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.

Thomas A. Blinka

Norman F. Oblon

Registration No. 24,618



22850

(703) 413-3000 (phone)
(703) 413-2220 (fax)

Thomas A. Blinka, Ph.D.
Registration No. 44,541

DOCKET NO: 216143US0DIV



IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF :

PHILIPPE MOULLIER, ET AL. :

EXAMINER: QIAN, C. X.

SERIAL NO: 09/987,601 :

FILED: NOVEMBER 15, 2001 :

GROUP ART UNIT: 1636

FOR: BIOCOMPATIBLE IMPLANT FOR :
THE EXPRESSION AND IN VIVO
SECRETION OF A THERAPEUTIC
SUBSTANCE

RECEIVED
AUG 28 2003
TECH CENTER 1600/2900

RESPONSE TO REQUIREMENT FOR RESTRICTION

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

In response to the Official Action of July 29, 2003, Applicants elect, with traverse,
Group I, Claims 61-71, drawn to an implant comprising a biocompatible support and
eukaryotic cells anchored onto the surface of the support.

Remarks begin at page 2 of this paper.